CYP3A5基因多态性与晚期非小细胞肺癌紫杉醇化疗敏感性关系的研究  

The Relationship between CYP3A5 Gene Polymorphisms and Sensitivity to Paclitaxel-based Chemotherapy in Advanced Non-small Cell Lung Cancer

作　　者：马洁云[1] 王建红[1] 张一心[1] 胡晓莉[1] 杨磊[1] 

机构地区：[1]南通市肿瘤医院,江苏南通226361

出　　处：《中国肿瘤》2014年第10期869-872,共4页China Cancer

摘　　要：[目的]探讨CYP3A5基因多态性与晚期非小细胞肺癌紫杉醇化疗敏感性的关系。[方法]对接受以紫杉醇为基础化疗方案进行化疗的60例晚期非小细胞肺癌患者,采用PCR-RFLP方法检测外周血CYP3A5*1/*3基因多态性,比较不同基因型之间紫杉醇化疗近期疗效的差异。[结果]60例患者中,CYP3A5基因为*1/*1、*1/*3和*3/*3型的患者数分别有6例(10.00%)、20例(33.33%)和34例(56.67%)。*1/*1和*1/*3基因型患者的有效率为19.23%,*3/*3基因型患者的有效率为55.88%,*1/*1和*1/*3基因型患者的有效率明显低于*3/*3基因型患者(P=0.004)。[结论]对非小细胞肺癌患者治疗前进行CYP3A5基因型的测定,可预测紫杉醇的化疗疗效。[Purpose] To investigate the relationship between CYP3A5 gene polymorphisms and sensitivity to paclitaxel-based chemotherapy in patients with advanced non-small cell lung cancer（NSCLC）. [Methods] Sixty cases with advanced NSCLC undergoing paclitaxel-based chemotherapy were enrolled. CYP3A5 genotypes were determined by PCR-RFLP,and the short term response was compared in patients with different CYP3A5 genotypes. [Results] The ＊1/＊1,＊1/＊3 and ＊3/＊3genotypes were presented in 6 patients（10.00%）,20 patients（33.33%） and 34 patients（56.67%）,respectively. The response to paclitaxel-based chemotherapy was 19.23% in patients with CYP3A5 ＊1/＊1 and ＊1/＊3,and 55.88% in patients with CYP3A5 ＊3/＊3. Patients with CYP3A5 ＊3/＊3 genetype had a higher response than that with CYP3A5 ＊1/＊1 and ＊1/＊3（P=0.04）. [Conclusion] CYP3A5 may be as an indicator for sensitivity to paclitaxel-based chemotherapy in patients with advanced non-small cell lung cancer.

关 键 词：CYP3A5 基因多态性 紫杉醇 非小细胞肺癌 化疗敏感性 

分 类 号：R734.2[医药卫生—肿瘤]